Enter your Email Address


Useful Links

Know What The Insiders Are Doing!
Stock Trading Software

More Links




[Most Recent Quotes from www.kitco.com]

[Most Recent Quotes from www.kitco.com]




PennyOmega.com Stocks Upgraded, Downgraded and Short Highlights Before the Bell Friday September 4, 2009

Penny Omega (September 4th, 2009) Writes:

 

PennyOmega.com Hot Stock News & Alerts!

________________________________________

FREE Daily Stock Alerts From PennyOmega.com

signup3m

________________________________________

 

Friday September 4, 2009

PennyOmega.com Stock Report!

**************************************************************

Callidus Software Inc. (NASDAQ: CALD), the leader in Sales Performance Management (SPM), today announced that Medical Mutual of Ohio has selected Callidus Software’s Insurance Suite and Business Process Management Suite (BPM) to manage its sales performance, incentive compensation programs and broker onboarding processes. Under the agreement, signed in the third quarter

...
More »
Tags for this Post:
Associate Professor, Callidus Software Inc.;, Cancers, Chief Financial Officer, China, China Technology Development Group Corporation, Company’s Nominating Committee, Delcath Systems Inc., Expert Group Inc., Florida, Fort Lauderdale, Frederick Tang, Gary Leung, Insurance Suite, International Liver Cancer Association, Italy, James F. Pingpank, leader in Sales Performance, manager, Medical Mutual of Ohio, medical technology, Medicines Company, melanomas, metastases, Milan, New Drug;, PennyOmega.com, PHP, Professor of Surgery, software applications, Solar Energy Products, stock featured on our site;, Stocks to Watch, Teva Parenteral Medicines Inc., TrueInformation®, U.S. Food and Drug Administration, United States, University of Pittsburgh School of Medicine, USD, Vice President

Posted in Stocks to Watch | No Comments »

EXXI, VIP, MDCO Stock-PR Stock Headlines September 4, 2009

stock-pr (September 4th, 2009) Writes:

Energy XXI (Bermuda) Limited (EXXI) Gulf Coast, Inc. (the “Company”) today September 4, 2009 announced it has commenced an exchange offer and consent solicitation in respect of its 10% Senior Notes due 2013 (the “Senior Notes”).

The Company has commenced an offer to exchange up to $360 million principal amount outstanding Senior Notes properly tendered (and not validly withdrawn) and accepted by the Company for its newly issued 16% Second Lien Junior Secured Notes due 2014 (the “Second Lien Notes”), subject to proration and reduction to $311 million principal amount of Senior Notes, depending on the aggregate principal amount of Second Lien Notes sold in a concurrent private placement.

About Energy XXI

Energy XXI is a Houston-based independent energy company engaged in the acquisition, development, exploration and production of oil and natural gas reserves in the U.S. Gulf Coast and the Gulf of Mexico. The Company an indirect wholly owned subsidiary of the

...
More »

Posted in Small & Micro Cap | No Comments »

BioMedReports.com Extreme Trades: ACAD, ANPI, BSTC, RPRX, SNTS

Bullish Bankers (June 16th, 2009) Writes:

Below are four companies with market caps under $200 million (all financial data current as of 6/9/09 during intraday trading) which have pending FDA decisions and/or clinical trial results that may have a major impact on each of the underlying stock prices. A high risk/reward trading approach to consider for speculative traders is investing a small amount of money that you can afford to lose in a basket of stocks included in Extreme FDA and Clinical Trial Calendar Trades, which are highlighted in periodic articles at BioMedReports.com. Another approach is to simply buy such companies well ahead of their expected catalyst dates for a possible stock price increase as the date approaches and trading activity increases.

1.) Angiotech Pharma [ANPI: 1.97, 0.00 (0.00%)] – currently trading at $2.14, market cap = $182 million

ANPI has an FDA-approved dialysis catheter (HemoStream) that is sold through its direct sales

...
More »
Tags for this Post:
5-FU anti-infective ;, 5-FU anti-infective technology;, anemia, ANPI;, anti-infective technology;, artery disease;, bicarbonate product;, BioSpecifics Technologies;, bullish bankers, California, Canada, cancer, contracture;, Cook Medical Inc.;, dialysis, endometriosis, Europe, Fda, Financial, Germany, HealthCare Products Inc.;, HemoStream;, implantable devices;, Japan, Korea, Market Commentary, Mike Havrilla, New Drug;, paclitaxel technology;, Pfizer, Proellex;, proton pump inhibitor products;, San Diego, Santarus Inc;, Schering Plough, Securities And Exchange Commission, Society of Interventional Radiology;, sodium bicarbonate;, stent product;, treatment of various types of cancer;, United States, USD, uterine fibroids;, Xiaflex;, Zegerid;, Zilver PTX stent;, Zilver PTX;, ZPE-201;, ZPU-301;, ZPU-302;

Posted in Financial, Market Commentary | No Comments »


Newsletter

No recommendations, either expressed or implied, are being made to buy, sell, hold or short any of the mentioned stocks. No legal, tax or accounting advice is expressed or implied. Always contact your attorney, CPA, or tax advisor before acting on any legal or tax issues. StraightStocks.com is not responsible for the content, products, or services of any of the advertisers on this site. StraightStocks.com receives compensation from advertisers on this blog. Services and products referred to herein are trademarks, registered trademarks, servicemarks, and/or registered servicemarks of their respective trademark or servicemark owners.